The global extensively drug-resistant tuberculosis (TB) response plan calls for
implementation of rapid tests to screen patients at risk of drug-resistant TB. Currently, two …

Background There is an urgent demand for rapid and accurate drug-susceptibility testing for
the detection of multidrug-resistant tuberculosis. The GenoType MTBDR plus assay is a …

Background One of the challenges facing the tuberculosis (TB) control programmes in
resource-limited settings is lack of rapid techniques for detection of drug resistant TB …

Only 25% of multidrug-resistant tuberculosis (MDR-TB) cases are currently diagnosed. Line
probe assays (LPAs) enable rapid drug-susceptibility testing for rifampicin (RIF) and …

Background To control multidrug resistant tuberculosis (MDR-TB), the drug susceptibility
profile is needed to guide therapy. Classical drug susceptibility testing (DST) may take up to …

To facilitate the management of multidrug-resistant (MDR) tuberculosis, two nucleic acid
sequence-based methods, the GenoType MTBDR plus test and DNA sequencing, were …

Molecular diagnostics for Mycobacterium tuberculosis have recently been endorsed by the
World Health Organization. The Xpert MTB/RIF assay was endorsed for use on patient …

Background Over the past several years, new diagnostic techniques have been developed
to allow for the rapid detection of multidrug resistant tuberculosis. The GenoType® MTBDR …

The commercially available line probe assay MTBDRplus 2.0 (Hain Lifescience, Nehren,
Germany) was evaluated for its ability to detect Mycobacterium tuberculosis complex …

Early detection of resistance to second-line antituberculosis drugs is important for the
management of multidrug-resistant tuberculosis (MDR-TB). The GenoType MTBDR sl …